ATE99358T1 - Alpha-1-antitrypsinmutante und dafuer kodierende dns und herstellung derselben, und solche mutante verwendende therapeutische zusammensetzungen und ihre herstellung. - Google Patents

Alpha-1-antitrypsinmutante und dafuer kodierende dns und herstellung derselben, und solche mutante verwendende therapeutische zusammensetzungen und ihre herstellung.

Info

Publication number
ATE99358T1
ATE99358T1 AT85301790T AT85301790T ATE99358T1 AT E99358 T1 ATE99358 T1 AT E99358T1 AT 85301790 T AT85301790 T AT 85301790T AT 85301790 T AT85301790 T AT 85301790T AT E99358 T1 ATE99358 T1 AT E99358T1
Authority
AT
Austria
Prior art keywords
mutants
production
alpha
dna encoding
therapeutic compositions
Prior art date
Application number
AT85301790T
Other languages
English (en)
Inventor
Margaret Y Insley
Glenn Kawasaki
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE99358T1 publication Critical patent/ATE99358T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT85301790T 1984-03-14 1985-03-14 Alpha-1-antitrypsinmutante und dafuer kodierende dns und herstellung derselben, und solche mutante verwendende therapeutische zusammensetzungen und ihre herstellung. ATE99358T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58941084A 1984-03-14 1984-03-14
US06/709,382 US4711848A (en) 1984-03-14 1985-03-07 Site specific mutagenesis in alpha-1-antitrypsin
EP85301790A EP0155188B1 (de) 1984-03-14 1985-03-14 Alpha-1-Antitrypsinmutante und dafür kodierende DNS und Herstellung derselben, und solche Mutante verwendende therapeutische Zusammensetzungen und ihre Herstellung

Publications (1)

Publication Number Publication Date
ATE99358T1 true ATE99358T1 (de) 1994-01-15

Family

ID=27080550

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85301790T ATE99358T1 (de) 1984-03-14 1985-03-14 Alpha-1-antitrypsinmutante und dafuer kodierende dns und herstellung derselben, und solche mutante verwendende therapeutische zusammensetzungen und ihre herstellung.

Country Status (7)

Country Link
US (1) US4711848A (de)
EP (2) EP0566158A1 (de)
JP (3) JP2539781B2 (de)
AT (1) ATE99358T1 (de)
AU (1) AU593766B2 (de)
CA (1) CA1341219C (de)
DE (1) DE3587703D1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8410063B (en) * 1984-01-30 1985-10-30 Smith Kline Rit Expression of human alpha-1-antitrypsin in yeast
DE3585969D1 (de) * 1984-06-14 1992-06-11 Chiron Corp Protease-inhibitoren des alpha-1-antitrypsin typs mit modifizierter aktiever stelle und deren herstellung.
US4732973A (en) * 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
WO1986000337A1 (fr) * 1984-06-19 1986-01-16 Transgene S.A. DERIVES DE L'alpha1-ANTITRYPSINE HUMAINE ET PROCEDE POUR LEUR PREPARATION
US5422090A (en) * 1984-08-13 1995-06-06 Biotechnology Australia, Pty., Ltd. Human PAI-2
CA1299120C (en) * 1984-10-22 1992-04-21 Glenn Kawasaki Stable dna constructs for expression of alpha-1-antitrypsin
US6291662B1 (en) 1984-12-05 2001-09-18 Amgen Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences
US5871956A (en) * 1984-12-06 1999-02-16 Amgen Inc. Recombinant methods for production of serine inhibitors and DNA sequences useful for same
AU591474B2 (en) * 1984-12-06 1989-12-07 Amgen, Inc. Serine protease inhibitors and methods for isolation of same
US6132990A (en) * 1984-12-06 2000-10-17 Amgen Boulder Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences useful for same
AU590238B2 (en) * 1984-12-06 1989-11-02 Amgen, Inc. Recombinant methods for production of serine protease inhibitors and dna sequences useful for same
US5900400A (en) * 1984-12-06 1999-05-04 Amgen Inc. Serine protease inhibitor analogs
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DK171161B1 (da) * 1985-03-28 1996-07-08 Hoffmann La Roche Fremgangsmåde til påvisning af forekomst eller fravær af mindst én specifik nukleinsyresekvens i en prøve eller til skelnen mellem to forskellige nukleinsyresekvenser i denne prøve
AU6469886A (en) * 1985-11-08 1987-05-14 Smithkline Beckman Corporation Mutant alpha-1-antitryosin and dna sequence therefor
FR2599752B1 (fr) * 1986-06-10 1989-11-03 Transgene Sa Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
EP0253193B1 (de) * 1986-07-08 1992-10-28 Abbott Laboratories Verfahren für die Mutagenese durch eine oligonukleotidgeleitete Reparatur eines Strangbruchs
JP2656944B2 (ja) * 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
NZ226543A (en) * 1987-10-22 1992-02-25 Merck & Co Inc Recombinant mutant acidic fibroblast growth factor
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5622845A (en) * 1988-02-17 1997-04-22 The Upjohn Company Fermentation method for producing norleucine
US5180667A (en) * 1988-03-07 1993-01-19 Ciba-Geigy Corporation Genes encoding eglin C mutants
EP0332576B1 (de) * 1988-03-07 1994-04-06 Ciba-Geigy Ag Modifizierte Proteine
DE3901917A1 (de) * 1989-01-24 1990-07-26 Behringwerke Ag Mutanten von humanem antithrombin iii
DK0401508T3 (da) * 1989-05-13 1995-05-15 Bayer Ag Proteaseinhibitorer, fremgangsmåde til deres fremstilling samt lægemidler med indhold deraf
US5518907A (en) * 1989-06-07 1996-05-21 Center For Innovative Technology Cloning and expression in Escherichia coli of the Alcaligenes eutrophus H16 poly-beta-hydroxybutyrate biosynthetic pathway
US5334520A (en) * 1990-05-25 1994-08-02 Center For Innovative Technology Production of poly-beta-hydroxybutyrate in transformed escherichia coli
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
AU7168591A (en) * 1989-12-29 1991-07-24 Zymogenetics Inc. Hybrid protein c
US6869925B1 (en) * 1992-09-09 2005-03-22 Amgen Inc. Inhibition of retrovirus infection
CA2170030A1 (en) * 1993-09-14 1995-03-23 Robert A. Lazarus Pharmaceutical compositions containing ecotin and homologs thereof
US6017880A (en) * 1994-03-09 2000-01-25 Amgen Inc. Inhibition of retrovirus infection
WO1996010638A1 (en) * 1994-09-30 1996-04-11 Ppl Therapeutics (Scotland) Ltd. Alpha-1-antitrypsin and antithrombine-iii variants
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US6315995B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US6316403B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
GB2318732A (en) 1996-11-01 1998-05-06 Johnson & Johnson Medical Wound healing compositions containing alpha-1-antitrypsin
AU743025B2 (en) 1997-03-12 2002-01-17 Applera Corporation DNA polymerases having improved labeled nucleotide incorporation properties
WO2000051625A1 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
AU3511500A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
AU3731400A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
US20050250688A1 (en) * 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
WO2002086088A2 (en) * 2001-04-24 2002-10-31 Li-Cor, Inc. Polymerases with charge-switch activity and methods of generating such polymerases
US20050042629A1 (en) 2002-09-13 2005-02-24 Applera Corporation Thermus scotoductus nucleic acid polymerases
WO2003048308A2 (en) 2001-11-30 2003-06-12 Applera Corporation Thermus brockianus nucleic acid polymerases
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
EP1660661A2 (de) * 2003-08-08 2006-05-31 Arriva Pharmaceuticals, Inc. Verfahren zur proteinproduktion in hefe
EP2520654B8 (de) 2003-08-26 2017-04-19 The Regents of the University of Colorado, a body corporate Serinprotease-Hemmer und deren Verwendung in Verfahren und Zusammensetzungen für die Behandlung bakterieller Infektionen
SI1684719T1 (sl) 2003-11-14 2012-07-31 Baxter Int Sestavki alfa antitripsina in postopki zdravljenja ob uporabi takih sestavkov
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
GB2446550B (en) * 2005-11-28 2010-12-08 Proteomtech Inc Methods for production of recombinant alpha1-antitrypsin
CA2672651C (en) 2006-12-15 2014-03-11 Lifebond Ltd. Gelatin-transglutaminase hemostatic dressings and sealants
US8133484B2 (en) 2006-12-15 2012-03-13 Lifebond Ltd Hemostatic materials and dressing
KR100992526B1 (ko) * 2007-11-21 2010-11-05 한국과학기술연구원 이황화결합을 이용한 내열성의 알파-1-안티트립신 뮤테인및 그의 제조방법
US20110112573A1 (en) * 2008-06-18 2011-05-12 Orahn Preiss Bloom Methods and devices for use with sealants
EP2303341A2 (de) * 2008-06-18 2011-04-06 Lifebond Ltd Verfahren zur enzymatischen vernetzung eines proteins
US8367388B2 (en) 2008-06-18 2013-02-05 Lifebond Ltd. Cross-linked compositions
EP2496246B1 (de) 2009-11-03 2018-06-27 Grifols Therapeutics LLC Zusammensetzung, verfahren und kit für einen alpha-1-proteasehmmer
CA2781120C (en) 2009-11-24 2015-01-27 Jianxin Guo Lyophilization methods, compositions, and kits
JP5796860B2 (ja) 2009-12-22 2015-10-21 ライフボンド リミテッドＬｉｆｅｂｏｎｄ Ｌｔｄ 架橋マトリックスの特性を調節するための酵素的架橋剤の改変
CA2807012A1 (en) 2010-08-05 2012-02-09 Lifebond Ltd. Dry composition wound dressings and adhesives
EP2668201A2 (de) 2011-01-28 2013-12-04 Sanofi Pasteur SA Immunologische zusammensetzungen mit hiv-gp41-polypeptidderivaten
EP2723370A4 (de) 2011-06-24 2015-06-03 Univ Colorado Regents Zusammensetzungen, verfahren und verwendung für alpha-1-antitrypsin-fusionsmoleküle
ES2656150T3 (es) * 2011-11-14 2018-02-23 Universitätsklinikum Jena Diagnóstico de la sepsis y del síndrome de respuesta inflamatoria sistémica
MY166314A (en) 2011-12-30 2018-06-25 Grifols Sa Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations
KR102348985B1 (ko) 2012-01-10 2022-01-12 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
EP2978442B1 (de) 2013-03-29 2020-03-18 The Regents of the University of Colorado, a body corporate Alpha 1 antitrypsin zur vorbereitung eines patienten auf ein transplantat
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
EP3397274A1 (de) 2015-12-31 2018-11-07 The Regents of the University of Colorado, a body corporate Verfahren und verwendungen für alpha-1-antitrypsin oder rekombinante formen davon auf steroid-refraktärer graft-versus-host-krankheit mit gastrointestinalen komplikationen
WO2018183705A1 (en) * 2017-03-29 2018-10-04 Cornell University Oxidation-resistant aat gene therapy
SE1750774A1 (en) * 2017-06-19 2018-12-11 Hepgene Medical Ab Novel nucleic acid molecules and their use in therapy
EP3723790B1 (de) 2017-12-12 2024-03-13 Kamada Ltd Verfahren zur induzierung der immuntoleranz und zur verminderung der antiinflammatorischen antikörperreaktion
WO2023083859A1 (en) 2021-11-09 2023-05-19 Danmarks Tekniske Universitet Variants of alpha-1-antitrypsin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351901A (en) * 1980-03-24 1982-09-28 Cetus Corporation Method for single nucleotide alteration
CA1303530C (en) * 1983-01-21 1992-06-16 Michael Courtney EXPRESSION VECTORS AND THEIR USE FOR THE PREPARATION OF A PROTEIN HAVING HUMAN .alpha. -ANTITRYPSIN ACTIVITY
JPS60186290A (ja) * 1983-08-10 1985-09-21 チモ−ジエネテイツクス　インコ−ポレ−テツド アルフア−１−アンチトリプシンを細菌に表現させる方法
AU3145184A (en) * 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
ZA8410063B (en) * 1984-01-30 1985-10-30 Smith Kline Rit Expression of human alpha-1-antitrypsin in yeast
DE3585969D1 (de) * 1984-06-14 1992-06-11 Chiron Corp Protease-inhibitoren des alpha-1-antitrypsin typs mit modifizierter aktiever stelle und deren herstellung.
WO1986000337A1 (fr) * 1984-06-19 1986-01-16 Transgene S.A. DERIVES DE L'alpha1-ANTITRYPSINE HUMAINE ET PROCEDE POUR LEUR PREPARATION

Also Published As

Publication number Publication date
JPH06105689A (ja) 1994-04-19
EP0155188A3 (en) 1986-08-13
DE3587703D1 (de) 1994-02-10
EP0155188A2 (de) 1985-09-18
EP0566158A1 (de) 1993-10-20
AU3981985A (en) 1985-09-19
JP2539781B2 (ja) 1996-10-02
CA1341219C (en) 2001-05-01
AU593766B2 (en) 1990-02-22
JPH10113193A (ja) 1998-05-06
EP0155188B1 (de) 1993-12-29
JP2750257B2 (ja) 1998-05-13
JPS6112289A (ja) 1986-01-20
US4711848A (en) 1987-12-08

Similar Documents

Publication Publication Date Title
ATE99358T1 (de) Alpha-1-antitrypsinmutante und dafuer kodierende dns und herstellung derselben, und solche mutante verwendende therapeutische zusammensetzungen und ihre herstellung.
CA2000786A1 (en) 3-piperidinyl-1,2-benzisoxazoles
CA2026915A1 (en) Stem cell factor
DK0732935T3 (da) Lyofiliserede stamcellefaktorformuleringer
MY106280A (en) Novel benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use.
DE3871751T2 (de) Gelbildende organosiloxanzusammensetzungen und deren verwendung.
IT8323205A0 (it) Composizioni farmaceutiche adattivita' antiinfiammatoria e/o analgesica, non ulcerogene.
DE3882593D1 (de) Polypeptid und dessen herstellung.
BG103096A (en) Thrombin inhibitors
DE3685282D1 (de) Rhombohedrisches polykristallines bornitrid und dessen herstellung.
DE3578304D1 (de) Pyridazinonderivate, deren herstellung und insektizidische, acaricidische, nematicidische, fungizidische zusammensetzungen.
DE3582895D1 (de) Peptid, dessen herstellung und benutzung.
DE3585095D1 (de) 6-alkyliden-peneme, ihre herstellung und verwendung sowie zwischenprodukte.
DE3577707D1 (de) 3-pyrazolo(1,5-a)pyridinium-cephemverbindungen, deren herstellung und verwendung.
IT1276162B1 (it) Geranilgeranil-derivati,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE69321687D1 (de) Durchlässige materialkomposition, durchlässiges material und dessen herstellung
DE3674789D1 (de) Balken und dessen herstellung.
DE3586952D1 (de) Fibrinophiler urokinase-komplex und dessen herstellung.
AU589933B2 (en) 8 alpha-acylaminoergoline, its production and pharmaceutical compositions containing it
EP0351795A3 (de) Deoxyadenosin-Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung
DE3584156D1 (de) Gif-2 und dessen herstellung.
IT8424266A0 (it) Composizioni farmaceutiche e loro uso come midriatici.
ZA858315B (en) 5-cyanopyridine-2-diazohydroxide,basic salts and methods for production and use
ES8605261A1 (es) Un procedimiento para la preparacion de 1,4-aminoalquilamino-9-h-tioxaten-9-onas.
AU578125B2 (en) Pyrazine diazohydroxide compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties